anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a method for identification of an antigenic peptide.  <P>SOLUTION: The method useful for isolating the antigenic peptide from a limited quantity of cells or bodily fluid derived from a mammalian organism in an amount sufficient to determine the sequence and identity is provided. Therefore the method for identifying novel disease-associated antigens, e.g. tumor antigens and antigens involved in autoimmune diseases, to be utilized for diagnostic or therapeutic purposes is provided. The methods can also be utilized for controlling the quality of vaccines. More specifically, the method can be used for determining the sequence of antigenic peptides presented via peptide receptors of dendritic cells which are the most important antigen presenting cells of the body and valuable tools for vaccination.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Many women seek treatment to improve menopausal vasomotor symptoms (VMS). The selection of women most likely to benefit from menopause hormone therapy (MHT) is crucial in clinical practice. There is general agreement that women younger than 60 years or who initiate MHT within the first 10 years of menopause, with no contraindications, have greater benefits considering symptomatic relief and additional advantages. This group may have the advantage of protection from osteoporosis and from other chronic diseases that affect postmenopausal women, namely cardiovascular disease (CVD). Cumulating evidence supports MHT for symptomatic women. However, inadequate use according to the needs of symptomatic women led to a burden of suffering worldwide. In recent years, the emergent use of non-regulated body-identical hormones (non-rBHT) can expose patients to potential harms. These hormone preparations are not regulated through the same tests of safety, efficacy or dosing consistency as regulated-BHT (r-BHT). The POESIT (Portugal + Spain + Italy) recommendations highlight the use of 17β-estradiol (E2) and micronized progesterone (P4) as the real r-BHT. In addition, the group emphasizes as an example the data from the REPLENISH study with 1 mg E2/100 mg P4. The combination of the two hormones in one convenient pill showed a clear reduction or elimination of hot flashes and an improvement in sleep quality and, consequently, quality of life. At the same time, this combination has shown high rates of amenorrhea and no significant impact on lipid, glucose or coagulation parameters. Both the REPLENISH study and a real-life retrospective study pointed to the possibility of a lower risk of venous thromboembolism (VTE) with this formulation than with other combinations.
High dose (6g) of Vistula tart cherry, freeze dried. 120-156 mg of anthocyanins, 16.14 kcal with 2.43 g, 0.006 g, 0.08 g for carbohydrates, fat and protein, respectively.
The construct of Clinical-High Risk for Psychosis (CHR-P) identifies young help-seeking subjects in putative prodromal stages of psychosis and is a central component of the Early Intervention (EI) paradigm in Mental Health, aimed at facilitating rapid entry into appropriate care pathways to prevent the onset of psychosis or mitigate is biopsychosocial consequences. This approach, which promotes an innovative culture of care for early, at risk situations, is inspired by a clinical staging concept as a guide to optimal treatment. The objective of this article is to map the existing guidelines in the field of CHR-P treatment recommendations, examine overlaps and differences, and critically evaluate blind spots to be addressed in future guideline updated. The search identified 9 guidelines focused on CHR-P or schizophrenia and other psychotic conditions but containing a specific section on CHR-P or prodromal psychosis. All guidelines acknowledge that psychosis is preceded by more or less pronounced prodromal stages, and most detail CHR-P criteria. Among guidelines, 8 out of 9 indicate cognitive-behavioural therapy as the best psychotherapeutic option and 7 out of 9 suggest that antipsychotics can be prescribed as second option in case psychosocial and/or other pharmacological interventions prove insufficient or inadequate in reducing clinical severity and subjective suffering. Antidepressants, mood stabilizers, and benzodiazepines were considered for the treatment of comorbid disorders. Only the European Psychiatric Association Guidance paper distinguished treatment recommendations for adults and minors. Agreements in treatment guidelines were discussed in light of recent meta-analytical evidences on pharmacological and non-pharmacological treatments for CHR-P, suggesting the need to provide an updated, age-sensitive consensus on how to manage CHR-P individuals.
Subjects suspected of having sleep disorders who are referred to a sleep study will be screened for potential participation in the study, according to the inclusion and exclusion criteria. Additionally, patients with comorbidities associated with central sleep apnea may be referred from cardiology related divisions, and screened for participation in the study. Recruited patients will be asked to sign an informed consent form. Subject demographic and medical information will be acquired from the subject himself and/or from the subject's medical chart and will be recorded on the appropriate case report forms.

The subjects will be admitted to the clinical sleep laboratory for one night, during which they will undergo conventional full night PSG recording with the standard PSG channels. The WP with finger probe and chest sensor will be worn by the subject simultaneous to PSG. A PSG system will be recording the signals and manual scoring will be performed blinded - without access to WP data. The WP analysis will be done automatically.
PROBLEM TO BE SOLVED: To provide an extract of Perilla frutescens var. crispa f. viridis. that is excellent in functions of enhancing the activity of in vivo antioxidation system and of increasing the expression of antioxidant enzyme, and to provide production methods for obtaining the same.SOLUTION: An extract of Perilla frutescens var. crispa f. viridis. having an antioxidant function which activates Nrf2-ARE pathway is obtained by a subcritical process using Perilla frutescens var. crispa f. viridis. as a raw material and using water as an extraction solvent, at the temperature of 140 to 230°C, under the pressure equal to or more than the saturation vapor pressure at each temperature. A production method of the extract having an antioxidant function that activates Nrf2-ARE pathway, comprises a subcritical process of performing the subcritical process.SELECTED DRAWING: Figure 1
PURPOSE:To provide the title agent free from side effects, giving excellent antineoplastic activity through immunity activation, esp. effective on diseases predominant in blood cells' tumors, containing a deacetylated chitin. CONSTITUTION:Crustacean or insectan external skeleton, etc., is put to hydrochloric acid and sodium hydroxide treatments to remove ash and proteins, and the resulting chitin, poly(N-acetyl-D-glucosamine) is put to alkali treatment into a deacetylated chitin. The objective antineoplastic agent contains this chitin. The present agent is suitable for diseases such as malignant tumors, among others, blood cells' tumors, esp. adult T-cell leukemia(ATL) as a T-cell- based leukemia, or Se zary syndrome.
Previous studies have preliminary proven the safety and efficacy of atorvastatin tablets in the treatment of Non-alcoholic fatty liver disease (NAFLD).However, the sample size of these studies is small and most studies use B-ultrasound or CT for semi-quantitative determination of liver fat content. The defects of evaluation methods seriously affect the accuracy of the studies. Also, antioxidant agents have been proposed as a potentially effective treatment. Vitamin E is a potent antioxidant compound, which has been tested in pediatric NAFLD because of the absence of side effects. Conflicting results have been reported in clinical trials, both in children and in adults. The project intends to adopt advanced proton magnetic resonance spectroscopy (1H-MRS) to non-invasively and precisely determine liver fat content and understand the change in liver fat content before and after the treatment with atorvastatin tablets or Vitamin E in NAFLD patients with abnormal lipid metabolism and type 2 diabetes. We also intend to compare the therapeutic effects of atorvastatin and Vitamin E in the treatment of NAFLD.
Young adult heavy drinkers, aged 21-30, will enroll in a laboratory alcohol administration study. In a simulated bar laboratory, participants will be administered oral alcohol with three vodka-based drinks. This procedure will allow collection of several measures, notably a widely used, validated measure of self-reported SR and multiple measures capturing facets of impulsive behavior prior to and following alcohol administration. Participants will be recruited through a number of means. Flyers will be posted and handed out in and around the various colleges, universities and technical schools in the Gainesville area as well as in other public areas. The study team will utilize the internet by posting brief solicitation messages on social media, newspaper sites, and classified advertising sites. These same brief messages will also be disseminated to students at the local colleges, universities and technical schools in the area via batch emails and list servs. When permitted, brief recruitment talks will be given verbally during class meetings at these local institutions. Verbal recruitment messages will contain the same material in the appended flyers and other advertisements. Copies of flyers will also be provided at the conclusion of these brief recruitment talks. Potential participants will complete an initial eligibility questionnaire over the phone or online. Participants who appear eligible based on the phone/web screen will be invited to attend an in-person screening appointment. If eligible, participants will be scheduled for two alcohol drinking sessions separated by a minimum of one and a maximum of seven days. After the second drinking session, participants will be scheduled for a follow-up appointment.
In pooled analyses of placebo-controlled trials of chronically administered antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with major depressive disorder (MDD). The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 1. 

ZURZUVAE does not directly affect monoaminergic systems. Consider changing the therapeutic regimen, including discontinuing ZURZUVAE, in patients whose depression becomes worse or who experience emergent suicidal thoughts and behaviors.
OBJECTIVE: This study aimed to determine repetitive transcranial magnetic stimulation, transcranial direct current stimulation, and cranial nerve noninvasive neuromodulation affect functional balance, gait speed, and walking cadence in stroke patients.
METHODS: We searched PubMed, Embase, Cochrane, and Scopus (June 22, 2022) for randomized controlled trials. Three reviewers independently performed data extraction and assessed the risk of bias. Network and pairwise meta-analyses were performed to assess indirect and direct comparisons.
RESULTS: We included 34 studies ( N = 915 patients). Sixty percent had moderate-to-high methodological quality. The meta-analyses showed positive effects of repetitive transcranial magnetic stimulation combined with rehabilitation therapy compared with sham on gait speed, walking cadence, and balance function with weighted mean differences and 95% confidence interval of 0.08 (0.03 to 0.13), 7.16 (3.217 to 11.103), and 3.05 (0.52 to 5.57), respectively. Transcranial direct current stimulation showed improvement on the time up and go test (-0.88 [-1.68 to -0.08]). From the surface under the cumulative ranking analyses, repetitive transcranial magnetic stimulation is the best ranked treatment for gait speed and functional balance improvement compared with transcranial direct current stimulation and sham interventions. There were not enough studies to include cranial nerve noninvasive neuromodulation in the meta-analysis.
CONCLUSIONS: Walking cadence and speed, functional balance significantly improved after repetitive transcranial magnetic stimulation with short-term effects, which were superior to that of transcranial direct current stimulation and sham treatments. Transcranial direct current stimulation showed short-term beneficial effects on the Time Up and Go test.
Compositions having a curable unsaturated compound, an adhesion promoter and curing agent which have a peak exotherm of less than 50.degree. C. are disclosed. The compositions when cured are flexible bioadhesives which are also disclosed. Non-curable diluents can be included in the compositions. Flexible bioadhesives formed on biological structures and having low peak exotherms upon curing of curable compositions to form the flexible bioadhesives are disclosed. Compositions having a curable unsaturated compound and a curing agent and a peak exotherm of less than 50.degree. C. are included in the invention.
Background and Objectives: Postoperative nausea and vomiting (PONV) is a common issue for females undergoing gynecological surgeries, including those assisted by robotic systems. Despite available prophylactic measures, the incidence of PONV remains high, negatively impacting recovery and increasing healthcare costs. This study evaluates whether preoperative gum chewing reduces the need for anti-emetic drugs in females undergoing robot-assisted laparoscopic surgery for benign ovarian mass. Materials and Methods: This prospective, single-blinded, randomized controlled trial enrolled 92 adult females scheduled for robot-assisted laparoscopic surgery to treat benign ovarian mass. Following exclusions, the remaining participants were randomly assigned to either a gum-chewing group or a no-gum-chewing group. The gum-chewing group chewed sugar-free gum for 15 min in the holding area before surgery. The primary outcome measured was the need for anti-emetics to control PONV during the first hour in the post-anesthesia care unit (PACU). Secondary outcomes included the number of anti-emetic requests. No preemptive anti-emetics were administered during surgery. Results: Out of the initial 92 patients, 88 were included in the final analysis, with 44 in each group. The incidence of PONV requiring anti-emetics in the PACU was significantly lower in the gum-chewing group (79.5%) compared to the no-gum-chewing group (95.5%). Additionally, the number of anti-emetic requests was higher in the no-gum-chewing group. No postoperative complications such as tooth or jaw pain/injury or gastric content regurgitation were reported. Conclusions: Preoperative gum chewing for 15 min immediately before surgery significantly reduced the incidence of PONV in females undergoing robot-assisted laparoscopic surgery for benign ovarian mass. This simple, non-pharmacological intervention improved patient comfort and reduced the need for anti-emetic medications without any adverse effects. Further studies are needed to confirm these findings and to develop guidelines for incorporating preoperative gum chewing into clinical practice.
To provide a radar system for dynamically monitoring and guiding ongoing clinical trials.SOLUTION: In a workflow of the system, a data space is partitioned into 3 primary regions comprising "favorable", "hopeful" and "undesirable" to reflect the status of a trial. The undesirable region comprises a futility region, and the favorable region comprises a successful region. Boundaries defining these regions are subject to adjustment as the clinical trial proceeds. Accumulative treatment effect, data trends, stopping boundaries, trajectory and other information are graphically displayed on a radar screen. The system learns from the observed and accumulated data and performs simulations to intelligently guide the trial. The system is used in re-analysis or diagnosis of clinical trials already completed, and provides guidance for clinical trial design or amendment.SELECTED DRAWING: Figure 4F
The present invention relates to a cosmetic product having a carrier impregnated with a cosmetic composition. More specifically, the cosmetic product includes a cosmetic container storing an impregnating member impregnated with the cosmetic composition and an impregnating member storing a different cosmetic composition in a separate manner. The impregnating member includes: a frame having a waterproof layer formed on the lower part; a carrier body carrying with the different cosmetic composition while being formed on the upper part of the waterproof layer of the frame; and through-holes discharging the content of the impregnating member while being arranged on the waterproof layer and the carrior body as well as being finished with upper and lower sealing sheets including separation handles on the upper and lower parts of the frame. When the user peels off the upper and lower sealing sheets, the frame is arranged on the upper end of the impregnating member. A puff is used to press the carrier body in the frame in order to discharge the cosmetic composition impregnated in the impregnating member through the through-holes while mixing the cosmetic composition with the different cosmetic composition impregnated in the carrier body to be applied to the puff at the same time. The cosmetic product has the carrier body impregnated with the cosmetic composition for using two or more types of cosmetic compositions at once. The cosmetic product includes: the cosmetic container storing the impregnating member impregnated with the cosmetic composition; and the carrier member which is arranged separately from the cosmetic container while being arranged on the impregnating member in use. The carrier body includes a frame, a waterproof layer formed on the frame, and the carrier body impregnated with the different cosmetic composition while being formed on the upper part of the waterproof layer of the frame. Waterproof through-holes are formed on the waterproof layer.
A hand-held device (1) for dispensing a metered quantity of a substance such as a pharmaceuticals, medicinal, or therapeutic substance, and applying that substance to the skin of a host animal. The device includes a hollow body (2) that can be grasped by the hand of a user, and a substance capsule (4) mounted within that body. The capsule includes a container (5) for the substance, and a nozzle (10) through which a quantity of the substance is dispensed, possibly in the form of a spray. The device also includes actuator means (6,9) connected to the interior of the substance container and operable to cause a metered quantity of the substance to be dispensed through the nozzle. The actuator means includes a valve that is selectively operable to prevent or permit pressurized contents of the container escaping in the form of an aerosol. The device also includes means for preventing or minimising unintentional loss of the stored substance. Substance emerging from the nozzle is received within a shroud (13) for confining the dispensed substance to a designated target area, and which may also function to position the nozzle at a suitable distance from the target area.
We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week). Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane). While controlling the time that a maximal contraction will maintained, the therapist will assure that the targeted musculature will being maximally loaded. Resistance will be applied to the dorsum of the foot just above the toes to resist dorsiflexion and to the plantar surface of the foot at the metatarsals to resist plantar flexion. After resistance training the athletes will go for plyometric exercises and will follow the following guidelines.Tubing Exercises and Plyometric Ankle Jumps Ankle Circles. Move just your foot and ankle, not your leg. Vary the stretch by tracing out the letters of the alphabet with your big toe.
PURPOSE:To provide an antiaromatase agent containing, as an active ingredient, a low toxic azole derivative having a non-steroid type chemical structure entire ly different from that of e.g. 4-hydroxyandrostenedione. CONSTITUTION:This antiaromatase agent containing compound (s) selected from azole derivatives of formula I (Y is N or CH; R1 and R2 are each H or 1-5C alkyl; R3 is halogen, 1-5C alkyl, haloalkyl, phenyl, cyano or nitro; n is an integer of 0-5), salts thereof and steric isomers thereof (for example, R1 and R2 are each H; R3 is 4-F; n is 1; Y is N). The configuration of the compound of the formula I is e.g. of a compound of formula II or III. This agent is especially useful for aromatic ring-bearing steroid hormone-dependent diseases such as breast cancer, prostate cancer, ovarian cancer, uterine cancer, pancreatic cancer, or Cushing's syndrome cancer.
The present disclosure provides methods of treating a biological tissue using a proton beam. A method includes the steps of: irradiating a proton beam to a biological tissue containing a reactant. The reactant includes a composite. The composite reacts with at least one proton from the proton beam and releases at least one α particle or γ rays. The α particle or γ rays reacts with the biological tissue. Another method includes the steps of: providing a reactant, the reactant comprising a composite; introducing the reactant into a biological tissue, the reactant being distributed in the biological tissue; and irradiating the biological tissue with the proton beam. The composite reacts with at least one proton from the proton beam to release at least one α particle or γ rays, and the α particle or the γ rays reacts with the biological tissue.